已收盤 08-08 16:00:00 美东时间
+1.810
+1.42%
Barclays analyst Andrew Mok maintains DaVita (NYSE:DVA) with a Equal-Weight and lowers the price target from $169 to $160.
08-07 21:14
DaVita shares are trading lower. The company reported Q2 financial results.
08-06 22:35
DaVita (NYSE:DVA) affirms FY2025 Adj EPS guidance from $10.20-$11.30 to $10.20-$11.30 vs $10.73 analyst estimate..
08-06 04:09
DENVER, Aug. 5, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2025. "We're reporting another solid quarter, fueled by ...
08-06 04:05
BioMarin beats Q2 expectations on strong enzyme therapy sales and raises full-year earnings and revenue guidance amid continued Voxzogo growth.
08-06 01:11
U.S. stock futures are inching higher on Tuesday, following a strong rally on Monday, with major benchmark indices in the green.
08-05 18:14
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
巴菲特旗下伯克希尔哈撒韦增持了价值约1.06亿美元的Sirius XM股票,并减持了DaVita(DVA.US)的股票、套现约2.3亿美元。
08-05 15:01
Berkshire Hathaway (NYSE:BRK.B) purchased approximately $106 million worth of Sirius XM Holdings (NASDAQ:SIRI) stock and sold about $230 million in DaVita (NYSE:DVA) shares, according to recent regula...
08-05 13:55
Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify
08-04 20:09